← Back to Clinical Trials
Recruiting NCT06320288

NCT06320288 Analysis of Trunk and Center of Mass Control Development During Gait in Children With Cerebral Palsy (VERTEBRAL)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06320288
Status Recruiting
Phase
Sponsor Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est
Condition Children With Cerebral Palsy
Study Type OBSERVATIONAL
Enrollment 270 participants
Start Date 2023-09-20
Primary Completion 2026-09

Eligibility & Interventions

Sex All sexes
Min Age 18 Months
Max Age 18 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 270 participants in total. It began in 2023-09-20 with a primary completion date of 2026-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

During the acquisition of posturokinetic abilities such as walking, postural control of the trunk is of paramount importance. Indeed, its development is strongly linked to the overall motor function of children. In cerebral palsy (CP), a term that refers to a set of motor disorders following a perinatal lesion, deficits in axial control are present from early childhood. These deficits are strongly correlated with the functional deficits observed in this population. In particular, during walking, deviations of the trunk (amplitudes, accelerations) are observed in the three planes of space. While recent literature increasingly questions the impact of trunk control deficit on the walking of children with CP, elements are still missing for a holistic understanding of the interaction between locomotor and postural disorders in children with CP. In particular, no study has focused on the deviations of trunk control and the center of mass (which is a global indicator of balance strategies) during the development and maturation of walking in children with CP. Therefore, the primary objective of this cross-sectional observational study will be to characterize the development of trunk control and center of mass during walking in children with CP.

Eligibility Criteria

Inclusion Criteria: * Children (\< 18 years) with cerebral palsy * GMFCS I to III * Independent walking with or without technical walking aids (walker, crutches, etc.) * Able to understand the instructions of various clinical assessments and functional explorations * Affiliated with a social security scheme Exclusion Criteria: Children with cerebral palsy * Neuro-orthopaedic surgery of the lower limbs or trunk within the last 12 months * Botulinum toxin A injections within the last 6 months * Therapeutic intervention targeting trunk control last 6 months Typically developing children * Surgery on lower limbs or trunk last 12 months * Neurological and/or orthopedic pathology that may influence gait

Contact & Investigator

Central Contact

Jonathan Pierret, PhD

✉ jonathan.pierret@ugecam.assurance-maladie.fr

📞 +33 3 82 52 6761

Frequently Asked Questions

Who can join the NCT06320288 clinical trial?

This trial is open to participants of all sexes, aged 18 Months or older, up to 18 Years, studying Children With Cerebral Palsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06320288 currently recruiting?

Yes, NCT06320288 is actively recruiting participants. Contact the research team at jonathan.pierret@ugecam.assurance-maladie.fr for enrollment information.

Where is the NCT06320288 trial being conducted?

This trial is being conducted at Nancy, France.

Who is sponsoring the NCT06320288 clinical trial?

NCT06320288 is sponsored by Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est. The trial plans to enroll 270 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology